Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5259054 | 1.00 | ADORA2A (0.48) | ADORA2AROCK2KDM4EGSK3BADORA1 | |
| SCHEMBL5257984 | 0.92 | ADORA2A (0.47) | ADORA2AROCK2KDM4EGSK3BADORA1 | |
| SCHEMBL5257987 | 0.92 | ADORA2A (0.47) | ADORA2AROCK2KDM4EGSK3BADORA1 | |
| SCHEMBL5259880 | 0.87 | ADORA2A (0.42) | ADORA2AADORA1MAPK1 | |
| SCHEMBL5260735 | 0.87 | ADORA2A (0.42) | ADORA2AADORA1MAPK1 | |
| SCHEMBL5261663 | 0.85 | DEGS1 (0.41) | ADORA2AROCK2MAPK1ROCK1 | |
| SCHEMBL5261657 | 0.85 | DEGS1 (0.41) | ADORA2AROCK2MAPK1ROCK1 | |
| SCHEMBL5263630 | 0.85 | KMT2A (0.44) | ADORA2AKDM4EGSK3BADORA1MAPK1 | |
| SCHEMBL5263036 | 0.85 | ADORA2A (0.38) | ADORA2AADORA1 | |
| SCHEMBL5263038 | 0.85 | ADORA2A (0.38) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309590-B1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-09-19 | — | — | EP | claimed |
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN (IT) | 2003-01-02 | — | — | US | claimed |
| US-6335342-B1 | 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-01-01 | — | — | US | claimed |
| EP-1309590-B1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-09-19 | — | — | EP | disclosed |
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN (IT) | 2003-01-02 | — | — | US | disclosed |
| US-6486322-B1 | Azaindole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2002-11-26 | — | — | US | disclosed |
| US-6335342-B1 | 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | FFAR4, AZI2, CNKSR1 | ADORA2A 1105/4885ROCK2 1932/4885KDM4E 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.